Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Bad
|
New words:
acetate, adenocarcinoma, adolescence, Alaska, antiviral, Arabia, ASR, bear, bendamustine, birth, blood, book, Bruton, BTK, build, bulk, capable, chemistry, chemoimmunotherapy, chlorambucil, CHMP, chromosome, classification, comparison, compelling, Condensed, confirmatory, constituted, contraindicated, contraindication, correlation, covalent, createdinter, customary, cycle, Deferral, del, destination, diagnostic, drawn, drew, EC, Empliciti, expedited, extranodal, FASB, fit, flagship, forma, gemcitabine, Genentech, Gosebruch, GSK, heart, Henry, history, HS, hypomethylating, ibrutinib, IMBRUVICA, immunostimulatory, inappropriate, induction, ineligible, inseparable, insignificant, Johnson, jurisdiction, levothyroxine, levprolide, loan, macroglobulinemia, mantle, MCL, meal, mediated, mission, MM, motor, ninety, noncurrent, notice, oil, older, ombitsavir, ovarian, palivizumab, pancrelipase, paricalcitol, partnership, pattern, penalty, placebo, plaque, precise, preliminary, principle, proration, protein, provisional, PRV, psychiatric, psychological, punitive, rank, rare, reclassification, refractory, rest, retroactively, reverted, rituximab, Sante, Saudi, Signaling, SIMADI, skin, sNDA, sodium, Stanley, stream, substance, TECHNIVIE, tender, thirteenth, traditional, tyrosine, unexpected, unsubordinated, unsuccessful, unsuitable, unvested, USP, VEF, verification, voucher, Waldenstrom, withdrawn, zone
Removed:
accuracy, advisor, agent, albuminuria, alpha, atrasentan, Biotest, brain, bundled, calculate, cardiac, Centocor, CEO, close, cognitive, comparable, conjugate, contact, creating, cytotoxic, declaratory, depended, description, designing, devalued, diabetic, disrupting, domain, dual, efficient, ending, estate, explored, expressing, factory, financially, function, guaranteed, half, HIB, Idec, immunoglobulin, implement, infringe, insight, interpretation, intracompany, Israel, lift, likewise, linking, master, Matrix, memory, methotrexate, modulator, molecular, mood, motion, multiemployer, Mylan, negotiated, negotiating, nephropathy, optimizing, organizational, Ortho, outsourcing, parent, Perrigo, prejudice, progression, pursuing, ranging, realign, reflective, removed, replicate, representative, resolved, Roxane, Russia, schizophrenia, sentence, Shanghai, shortened, Simponi, space, sponsor, sponsored, stay, subtraction, surgery, syndicate, territorial, track, transitional, transitioning, travel, tregalizumab, tumor, unchanged, underserved, USA, verify, warehouse
Filing tables
Filing exhibits
Related press release
ABBV similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
- (1)
- Registration Statement (Form S-8 No. 333-185561) pertaining to the AbbVie 2013 Incentive Stock Program,
- (2)
- Registration Statement (Form S-8 No. 333-185562) pertaining to the AbbVie 2013 Employee Stock Purchase Plan for Non-U.S. Employees,
- (3)
- Registration Statement (Form S-8 No. 333-185563) pertaining to the AbbVie Deferred Compensation Plan,
- (4)
- Registration Statement (Form S-8 No. 333-185564) pertaining to the AbbVie Savings Program,
- (5)
- Registration Statement (Form S-3 No. 333-203677) pertaining to debt securities of AbbVie Inc.,
- (6)
- Registration Statement (Form S-8 No. 333-204466) pertaining to the Pharmacyclics, Inc. 2014 Equity Incentive Awards Plan, and
- (7)
- Registration Statement (Form S-3 No. 333-207422) pertaining to the AbbVie 2013 Incentive Stock Program;
of our reports dated February 19, 2016, with respect to the consolidated financial statements of AbbVie Inc. and subsidiaries and the effectiveness of internal control over financial reporting of AbbVie Inc. and subsidiaries included in this Annual Report (Form 10-K) of AbbVie Inc. and subsidiaries for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Chicago, Illinois
February 19, 2016
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM